文献速递肾癌与肾肿瘤

纳武利尤单抗序贯伊匹木单抗联合纳武利尤单抗治疗晚期非透明细胞肾细胞癌的II期试验

A phase II trial of nivolumab followed by ipilimumab and nivolumab in advanced non-clear-cell renal cell carcinoma.
PubMed 文献 · BJU Int · 2023-11-20

UNISoN(ANZUP1602;NCT03177239)是一项开放标签、单臂、II期临床试验,纳入83例免疫治疗初治的晚期非透明细胞肾细胞癌成人患者,先接受纳武利尤单抗单药治疗(Part 1),疾病进展后序贯加用伊匹木单抗(Part 2)。Part 1客观肿瘤缓解率为16.9%(95%CI 9.5-26.7),Part 2为10%;研究结论认为序贯联合免疫治疗策略未获支持,仅少数患者获益。

要点

  • Part 1纳武利尤单抗单药客观缓解率16.9%,中位缓解持续时间20.7个月。
  • Part 2序贯加用伊匹木单抗后客观缓解率10%,中位无进展生存期2.6个月。
  • Part 2治疗相关不良事件发生率80%,49%为3、4或5级。

核心结论

  • 纳武利尤单抗单药总体效果有限,少数患者获得较长缓解持续时间。
  • 在非透明细胞肾细胞癌中,纳武利尤单抗疾病进展后序贯加用伊匹木单抗的联合免疫治疗策略未获本研究支持,仅少数患者从中获益。

研究设计与样本

  • UNISoN(ANZUP1602;NCT03177239)为开放标签、单臂、II期临床试验,招募免疫治疗初治的晚期非透明细胞肾细胞癌成人患者。
  • Part 1:纳武利尤单抗240 mg静脉注射,每两周一次,最长12个月。
  • Part 2:治疗期间出现疾病进展者,序贯加用伊匹木单抗1 mg/kg,每三周一次,共四剂,联合纳武利尤单抗。
  • 主要终点为客观肿瘤缓解率,次要终点包括缓解持续时间、无进展生存期、总生存期和毒性(治疗相关不良事件)。
  • Part 1共83例符合条件,Part 2入组41例;中位(范围)随访22(16-30)个月。

主要发现

  • Part 1人群包括乳头状(37/83,45%)、嫌色细胞(15/83,18%)和其他非透明细胞肾细胞癌亚型(31/83,37%)。
  • Part 1客观肿瘤缓解率16.9%(95%CI 9.5-26.7),中位缓解持续时间20.7个月(95%CI 3.7-未达到),中位无进展生存期4.0个月(95%CI 3.6-7.4)。
  • Part 1治疗相关不良事件发生率71%,其中19%为3或4级。
  • Part 2客观肿瘤缓解率10%,中位缓解持续时间13.5个月(95%CI 4.8-19.7),中位无进展生存期2.6个月(95%CI 2.2-3.8)。
  • Part 2治疗相关不良事件发生率80%,49%为3、4或5级;自Part 1入组起中位总生存期24个月(95%CI 16-28)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To evaluate the efficacy of sequential treatment with ipilimumab and nivolumab following progression on nivolumab monotherapy in individuals with advanced, non-clear-cell renal cell carcinoma (nccRCC). MATERIALS AND METHODS: UNISoN (ANZUP1602; NCT03177239) was an open-label, single-arm, phase 2 clinical trial that recruited adults with immunotherapy-naïve, advanced nccRCC. Participants received nivolumab 240 mg i.v. two-weekly for up to 12 months (Part 1), followed by sequential addition of ipilimumab 1 mg/kg three-weekly for four doses to nivolumab if disease progression occurred during treatment (Part 2). The primary endpoint was objective tumour response rate (OTRR) and secondary endpoints included duration of response (DOR), progression-free (PFS) and overall survival (OS), and toxicity (treatment-related adverse events). RESULTS: A total of 83 participants were eligible for Part 1, including people with papillary (37/83, 45%), chromophobe (15/83, 18%) and other nccRCC subtypes (31/83, 37%); 41 participants enrolled in Part 2. The median (range) follow-up was 22 (16-30) months. In Part 1, the OTRR was 16.9% (95% confidence interval [CI] 9.5-26.7), the median DOR was 20.7 months (95% CI 3.7-not reached) and the median PFS was 4.0 months (95% CI 3.6-7.4). Treatment-related adverse events were reported in 71% of participants; 19% were grade 3 or 4. For participants who enrolled in Part 2, the OTRR was 10%; the median DOR was 13.5 months (95% CI 4.8-19.7) and the median PFS 2.6 months (95% CI 2.2-3.8). Treatment-related adverse events occurred in 80% of these participants; 49% had grade 3, 4 or 5. The median OS was 24 months (95% CI 16-28) from time of enrolment in Part 1. CONCLUSIONS: Nivolumab monotherapy had a modest effect overall, with a few participants experiencing a long DOR. Sequential combination immunotherapy by addition of ipilimumab in the context of disease progression to nivolumab in nccRCC is not supported by this study, with only a minority of participants benefiting from this strategy.

来源:BJU Int,查看原文。版权归原作者所有。

引用

  1. Conduit C, Davis ID, Goh JC, et al. A phase II trial of nivolumab followed by ipilimumab and nivolumab in advanced non-clear-cell renal cell carcinoma. BJU Int. 2023. PMID: 37986556. doi:10.1111/bju.16190

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。